SYP, together with bio companies from Daedeok Innopolis and Gimhae Innopolis, participated in Asia's flagship partnering events—'BioJapan 2026' in Yokohama and 'Medical Japan Tokyo 2026' in Chiba—arranging a total of 39 targeted 1-on-1 business matching meetings.

Key commercialization outcomes from the partnering sessions include:

• Target Link Therapeutics: Engaged in technical discussions with Astellas Pharma regarding its dual-payload ADC platform, scheduling a follow-up review in November upon additional data acquisition. The firm also initiated discussions with FUJIFILM CDMO for a domestic in-person meeting.

• MEDINO: Advanced joint research and GMP manufacturing discussions for intranasally administered exosome-based Parkinson's disease treatments with Taiwan’s AM BioTech, while exchanging safety data with global pharmaceutical distributors including R-Pharm and Alfresa.

• CUePEAKBio: Received a proposal from Japanese bio firm Setolabo for collaborative clinical research and companion diagnostics.

• REWALK & OPILEX: Explored integration opportunities for bed-care solutions with Charder Electronic and operated an exhibition booth to identify local medical and quasi-drug distributors.

SYP provided on-site advisory and interpretation to maximize meeting efficacy and will continue supporting follow-on discussions with prospective overseas partners